Type 2 diabetes associated with increased risk of colorectal cancer
the ONA take:
According to a new study published in the journal Diabetes Care, researchers from the Utrecht University Institute of Pharmaceutical Sciences in Utrecht, the Netherlands, have found that type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
For the study, researchers sought to investigate the risk of colorectal cancer in patients with type 2 diabetes and to assess whether treatment stage and duration of obesity affect that risk.
They identified 2,759 patients with type 2 diabetes and colorectal cancer after a median follow-up of 4.5 years from the Clinical Practice Research Datalink. All patients were on at least one prescription drug for type 2 diabetes. Results showed that type 2 diabetes was linked with a 1.3-fold increased risk for developing colorectal cancer (HR = 1.26; 95% CI: 1.18 - 1.33).
There was no association between treatment stages and colorectal cancer risk, but patients with obesity for 4 to 8 years (HR = 1.19; 95% CI: 1.06 - 1.34) and those with obesity for more than 8 years (HR = 1.28; 95% CI: 1.11 - 1.49) had a significantly increased risk of colorectal cancer.
The findings suggest that patients with type 2 diabetes, especially those who have been obese for 4 or more years, have an increased risk for developing colorectal cancer.
Type 2 diabetes is associated with a moderately increased risk of colorectal cancer.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|